Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy
Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy
复制标题
阿尔茨海默氏病成像生物标志物的比较：使用 [18F]florbetapir 正电子发射断层扫描的淀粉样蛋白成像和基于磁共振成像体素的内嗅皮质萎缩分析
DOI：
10.1002/gps.4173
复制
发表时间：
2014
影响因子：
4
通讯作者：
Okubo Y.
中科院分区：
文献类型：
--
作者：
Tateno A;Sakayori T;Kawashima Y;Higuchi M;Suhara T;Mizumura S;Mintun MA;Skovronsky DM;Honjo K;Ishihara K;Kumita S;Suzuki H;Okubo Y.
我们比较了临床诊断为阿尔茨海默病（AD）、轻度认知障碍（MCI）和老年健康对照（OHC）的受试者的淀粉样蛋白正电子发射断层扫描（PET）和磁共振成像（MRI），以测试这些成像生物标志物如何代表AD中的认知下降。19例AD患者通过[18 F]florbetapir PET检查，以量化标准摄取值比率（SUVR）作为淀粉样蛋白积聚程度，通过MRI和基于体素的AD特异性区域分析系统计算z评分作为内嗅皮质萎缩程度，以及简易精神状态检查（MMSE）和阿尔茨海默病评估量表-认知成分-日语版结果测量淀粉样蛋白AD样水平的两个截止值（SUVR为1.099）和内嗅皮质萎缩（z评分为1.60）与OHC有很好的鉴别诊断和临床定义的AD（SUVR为84.2%，z评分为86.7%）。基于β-淀粉样蛋白阳性的亚组分析显示，z评分仅在β-淀粉样蛋白受试者中与MMSE（r= − 0.626，p < 0.01）和ADAS-Jcog（r= 0.691，p < 0.01）显著相关。与OHC相比，[18 F]florbetapir PET和MRI均检测到AD的变化。考虑到内嗅皮质萎缩仅与β-淀粉样蛋白受试者的认知下降密切相关，[18 F]florbetapir PET可以在早期检测AD病理学，而β-淀粉样蛋白受试者的MRI形态测量学提供了评估晚期AD严重程度的良好生物标志物。版权所有© 2014约翰威利父子有限公司.
ObjectiveWe compared amyloid positron emission tomography (PET) and magnetic resonance imaging (MRI) in subjects clinically diagnosed with Alzheimer's disease (AD), mild cognitive impairment (MCI), and older healthy controls (OHC) in order to test how these imaging biomarkers represent cognitive decline in AD.MethodsFifteen OHC, 19 patients with MCI, and 19 patients with AD were examined by [18F]florbetapir PET to quantify the standard uptake value ratio (SUVR) as the degree of amyloid accumulation, by MRI and the voxel‐based specific regional analysis system for AD to calculatez‐score as the degree of entorhinal cortex atrophy, and by mini‐mental state examination (MMSE) and Alzheimer's Disease Assessment Scale–cognitive component—Japanese version (ADAS‐Jcog) for cognitive functions.ResultsBoth cutoff values for measuring AD‐like levels of amyloid (1.099 for SUVR) and entorhinal cortex atrophy (1.60 forz‐score) were well differentially diagnosed and clinically defined AD from OHC (84.2% for SUVR and 86.7% forz‐score). Subgroup analysis based on beta‐amyloid positivity revealed thatz‐score significantly correlated with MMSE (r= −0.626,p< 0.01) and ADAS‐Jcog (r= 0.691,p< 0.01) only among subjects with beta‐amyloid.ConclusionsThis is the first study to compare [18F]florbetapir PET and MRI voxel‐based analysis of entorhinal cortex atrophy for AD. Both [18F]florbetapir PET and MRI detected changes in AD compared with OHC. Considering that entorhinal cortex atrophy correlated well with cognitive decline only among subjects with beta‐amyloid, [18F]florbetapir PET makes it possible to detect AD pathology in the early stage, whereas MRI morphometry for subjects with beta‐amyloid provides a good biomarker to assess the severity of AD in the later stage. Copyright © 2014 John Wiley & Sons, Ltd.